Has Angeli Mayadev, MD received payments from drug or device companies?

Yes. Drug and device makers reported $51,055 in general payments to Angeli Mayadev, MD across 78 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Angeli Mayadev, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Angeli Mayadev, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Angeli Mayadev, MD

Physical Medicine & Rehabilitation · Seattle, WANPI 1891804530

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $41,463 of the $51,055 with a category attached, or 81.2%. AbbVie accounts for 89.0% of it on its own, with 10 other manufacturers making up the rest. Among physical medicine & rehabilitation clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$51,055in general payments, 2019–2025

Across 78 payments — averaging $654.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$45K
Ipsen Biopharmaceuticals, Inc$4K
F. Hoffmann-la Roche AG$900
Novartis$332
Boston Scientific$196
Bristol Myers Squibb$125
plus $309 from 5 others

$108,388in research payments, 2019–2025

Across 74 payments — averaging $1464.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Adamas Pharmaceuticals, Inc.$66K
Ipsen Pharma SAS$43K

What the payments were for

Consulting fees$5,95012%
Speaking & faculty fees$41,46381%
Travel & lodging$1,9244%
Food & beverage$1,7193%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	57	$45,442
Ipsen Biopharmaceuticals, Inc	5	$3,751
F. Hoffmann-la Roche AG	1	$900
Novartis	4	$332
Boston Scientific	3	$196
Bristol Myers Squibb	1	$125
Jazz Pharmaceuticals Inc.	1	$114
Biogen	1	$100
TG Therapeutics, Inc.	2	$41
Genentech USA, Inc.	2	$38
Genentech, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX$43,379
DYSPORT$3,650
BOTOX COSMETIC$1,400
KESIMPTA$127
Ozanimod$125
Epidiolex$114
VERCISE$110

How this compares

$51,055 in reported general payments places this provider in the 95th percentile of 260 physical medicine & rehabilitation providers in Washington.

See all physical medicine & rehabilitation providers in Washington →

Medicare billing

Part B allowed, 2024

$248,392

Medicare patients

170

Services billed

24,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Baclofen	269	$11,117
Gabapentin	182	$5,192
Carbamazepine ErCarbamazepine	13	$4,203
Tizanidine Hcl	87	$2,713
AmantadineAmantadine Hcl	19	$1,814
Carbamazepine	15	$755
Buprenorphine Hcl	11	$664
Cyclobenzaprine Hcl	27	$606
Duloxetine Hcl	13	$522
Oxybutynin Chloride	20	$514
Modafinil	18	$401
Nortriptyline Hcl	26	$342
Pramipexole DihydrochloridePramipexole Di-Hcl	12	$325
Diclofenac Sodium	19	$275
Oxcarbazepine	16	$226

Paid to pharmacies, not to this prescriber.

Other physical medicine & rehabilitation in Seattle

Nassim RadSeattle$231K
Martin ChildersSeattle$170K
Gavin NixonSeattle$8K
Aaron ButlerSeattle$4K
Alexander LloydSeattle$3K
Christopher IdeenSeattle$2K
Christopher BurtonSeattle$2K
Alfred GellhornSeattle$2K
Kirsten GageSeattle$2K
Jeffrey HeckmanSeattle$2K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →